Trial Profile
Phase II Study of Blinatumomab in Patients With B-cell Lineage Acute Lymphocytic Leukemia With Positive Minimal Residual Disease
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 30 Aug 2023
Price :
$35
*
At a glance
- Drugs Blinatumomab (Primary)
- Indications Precursor B-cell lymphoblastic leukaemia-lymphoma; Precursor cell lymphoblastic leukaemia-lymphoma
- Focus Therapeutic Use
- 15 Aug 2023 Planned End Date changed from 30 Sep 2023 to 30 Sep 2024.
- 15 Aug 2023 Planned primary completion date changed from 30 Sep 2023 to 30 Sep 2024.
- 22 Feb 2023 Planned End Date changed from 30 Sep 2022 to 30 Sep 2023.